KYTX at a glance
Kyverna Therapeutics Inc (KYTX, SEC CIK 1994702) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on September 24, 2026 and Form 4 insider filings as recently as May 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Kyverna Therapeutics Inc (KYTX) shares worth $141.7 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 23 funds
- $141.7M · +0 vs prior quarter
- Latest 10-Q
- Aug 11, 2026
- Quarterly report
SignalX for KYTX
Don't miss the next KYTX filing
- Alerts as it files. A push when KYTX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut KYTX, by share count.
- Ask anything. An AI agent that reads every KYTX filing and answers with sources.
KYTX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Shaw Christi | F | May 27, 2026 | 4,194 | $8.59 |
| CLARK IAN T | A | May 27, 2026 | 20,582 | - |
| SEIDENBERG BETH C | A | May 27, 2026 | 5,093 | - |
| SEIDENBERG BETH C | A | May 27, 2026 | 20,582 | - |
| Cohen Fred E | A | May 27, 2026 | 5,093 | - |
| Cohen Fred E | A | May 27, 2026 | 20,582 | - |
| Aktar Mert | A | May 27, 2026 | 5,093 | - |
| Aktar Mert | A | May 27, 2026 | 20,582 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$62.4M | -$142.6M | -$169.8M |
| Net Income | - | -$127.5M | -$161.3M |
| Balance Sheet | |||
| Total Assets | $75.2M | $304.6M | $293.8M |
| Equity | -$131.4M | $266.6M | $232.3M |
| ROE | - | -47.8% | -69.4% |
| Per Share | |||
| EPS | $-89.61 | $-3.33 | $-3.64 |
| Cash Flow | |||
| Operating CF | -$52.4M | -$114.3M | -$153.7M |
| CapEx | $621K | $2.2M | $5K |
Source: XBRL data in Kyverna Therapeutics Inc (KYTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate KYTX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 23 | $141.7M |
| Q1 2026 | 23 | $108.9M |
| Q4 2025 | 21 | $108.8M |
| Q3 2025 | 21 | $57.3M |
| Q2 2025 | 21 | $31.4M |
| Q1 2025 | 18 | $16.6M |
| Q4 2024 | 14 | $31.0M |
| Q3 2024 | 11 | $16.7M |
- BlackRock+2.26M (+257%)
- State Street Corp+843.9K (+610%)
- Wells Fargo & Co+258.6K (+226%)
- Northern Trust+237.3K (+304%)
- Bank of America Corp+209.7K (+376%)
- T. Rowe Price Group−369.3K (-24%)
- Millennium Management−365.7K (-36%)
- D.E. Shaw & Co−252.2K (-35%)
- Invesco Ltd−130.9K (-70%)
- Two Sigma Investments−130.3K (-72%)
- Vanguard Portfolio Management LLC+282.2K
- BNY Mellon+100.3K
- Mangrove Partners−27.0K
- Raymond James Financial−16.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 152 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
KYTX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
KYTX SEC filings: frequently asked questions
Which institutions hold KYTX stock?
As of June 30, 2026, the largest Kyverna Therapeutics Inc (KYTX) holders among the 13F filers tracked by SignalX were Gilead Sciences ($36.8 million), BlackRock ($27.9 million), Vanguard Capital Management LLC ($16.9 million), T. Rowe Price Group ($10.6 million), State Street Corp ($8.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the latest KYTX SEC filings?
Kyverna Therapeutics Inc (KYTX) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on September 24, 2026 and a Form 4 insider filing on May 29, 2026.
What is KYTX's SEC CIK number?
Kyverna Therapeutics Inc (KYTX)'s SEC Central Index Key (CIK) is 1994702. EDGAR lists every KYTX filing under that number.
Ask anything about KYTX
The research agent reads KYTX's filings, financials, insider trades and 13F holders, then answers with sources.